APA (7th ed.) Citation

P, C., M, F., S, R., A, G., C, Z., AM, F., . . . M, H. (2022). Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): A multicentre, open-label, phase 2 trial. The Lancet. Haematology, 9(10), e745. https://doi.org/10.1016/S2352-3026(22)00211-3

Chicago Style (17th ed.) Citation

P, Cramer, et al. "Obinutuzumab, Acalabrutinib, and Venetoclax, After an Optional Debulking with Bendamustine in Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL2-BAAG): A Multicentre, Open-label, Phase 2 Trial." The Lancet. Haematology 9, no. 10 (2022): e745. https://doi.org/10.1016/S2352-3026(22)00211-3.

MLA (9th ed.) Citation

P, Cramer, et al. "Obinutuzumab, Acalabrutinib, and Venetoclax, After an Optional Debulking with Bendamustine in Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL2-BAAG): A Multicentre, Open-label, Phase 2 Trial." The Lancet. Haematology, vol. 9, no. 10, 2022, p. e745, https://doi.org/10.1016/S2352-3026(22)00211-3.